MAB療法による間質性肺炎

Interstitial pneumonitis induced by bicaltamide and goserelin acetate for prostate cancer

　症例は85歳，男性。前立腺癌（低分化型腺癌，臨床病期C）と診断され，ビカルタミドと酢酸リュープロレリンによるMAB療法を開始した。MAB療法開始から16週間後，38℃の発熱と呼吸困難が出現し，ビカルタミドによる薬剤性間質性肺炎と診断し，ビカルタミドを中止した。ビカルタミド中止後，症状改善傾向であったためステロイドパルス療法は施行しなかった。

　A 85-year-old male received bicaltamide and leuprorelin acetate for stage C prostate cancer. 16 weeks after bicaltamide treatment,he complained of dyspnea and fever,and then administration of bicaltamide was discontinued. The chest X-ray demonstrating pulmonary fibrosis,was diagnosed as interstitial pneumonitis. 3 weeks after bicaltamide was stopped,his condition became improved without giving steroid pulse therapy. Interstitial pneumonia as one of the possible life-threatening complications should of great concern during treatment with MAB therapy for prostate cancer.